The collaboration is around developing a proof of concept lab to allow researchers to benchmark the latest mass spectrometric and UHPLC technologies, software, methodologies and workflows.
It will expand mass spectrometry, proteomics and lipidomics capabilities within the biomedical research precinct.
Thermo Fisher Scientific has revenues of $17bn and more than 50,000 employees in 50 countries.
“The coming together of Thermo Fisher and the University of Melbourne’s Bio21 Institute allows us to draw from the considerable collective expertise that resides across both teams resulting in comprehensive solutions to complex research and pharmaceutical application challenges for our customers,” said Amit Agarwal, MD of Thermo Fisher Scientific, ANZ.
The Bio21 Institute opened in 2005 and is one of largest molecular science and biotechnology research centres in Australia, accommodating more than 550 researchers.
Professor Malcolm McConville, director, Bio21 Institute, said the collaboration between academic researchers and Thermo Fisher will result in exciting new applications and informatics tools.
“This collaboration represents an excellent opportunity to build capacity and ensure that University researchers have access to the latest mass spectrometry instrumentation and proteomics workflows in this fast evolving field.”
Professor James McCluskey, University of Melbourne’s deputy vice-chancellor (Research), said the university-industry partnership builds on existing investments.
“It will enable greater knowledge and technology transfer, and ensure Australian research is translated into positive health outcomes in the future.”
The Mass Spectrometry and Proteomics Facility (MSPF) is equipped with UHPLC (Ultra High Performance Liquid Chromatography), MALDI (Matrix Assisted Laser Desorption/Ionization), low resolution and ultra-high resolution mass spectrometry, for proteomic and chemical analysis.